Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase sensitizes human osteosarcoma cells to anticancer drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 595-600

  Fromigué, Olivia ^a   Hamidouche, Zahia ^a   Marie, Pierre J ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CISPLATIN; DOXORUBICIN; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; STATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MMP2 PROTEIN, HUMAN; PYRROLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; CELL MOTION; CELL SURVIVAL; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; OSTEOSARCOMA; PYRROLES;

EID: 42449140710     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.136127     Document Type: Article

References (26)

1. Aznar S and Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165:1-10.
2. Blavier L, Lazaryev A, Dorey F, Shackleford GM, and DeClerck YA (2006) Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 66:2691-2699.
3. Bruland OS, Hoifodt H, Saeter G, Smeland S, and Fodstad O (2005) Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11:4666-4673.
4. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, and Kolodney MS (2003) Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2:941-948.
5. Coussens LM, Fingleton B, and Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392.
6. Ding HF and Fisher DE (2002) Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med 34:451-469.
7. Egeblad M and Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
8. Fromigué O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P, and Marie PJ (2006) RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 13:1845-1856.
9. Graaf MR, Richel DJ, van Noorden CJ, and Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609-641.
10. Guo P, Imanishi Y, Cackowski FC, Jarzynka MJ, Tao HQ, Nishikawa R, Hirose T, Hu B, and Cheng SY (2005) Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 166:877-890.
11. Himelstein BP (1998) Osteosarcoma and other bone cancers. Curr Opin Oncol 10:326-333.
12. Horiguchi A, Sumitomo M, Asakuma J, Asano T, and Hayakawa M (2004) 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10:8648-8655.
13. Johnstone RW, Ruefli AA, and Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164.
14. Kusama T, Mukai M, Endo H, Ishikawa O, Tatsuta M, Nakamura H, and Inoue M (2006) Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci 97:848-853.
15. Li YC, Park MJ, Ye SK, Kim CW, and Kim YN (2006) Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168:1107-1118.
16. Lowe SW and Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495.
17. Rochet N, Dubousset J, Mazeau C, Zanghellini E, Farges MF, de Novion HS, Chompret A, Delpech B, Cattan N, Frenay M, et al. (1999) Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int J Cancer 82:282-285.
18. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, Shull S, Mann K, and Rodan GA (1987) Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 47:4961-4966.
19. Stenner-Liewen F and Reed JC (2003) Apoptosis and cancer: basic mechanisms and therapeutic opportunities in the postgenomic era. Cancer Res 63:263-268.
20. Sternlicht MD and Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
21. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491.
22. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, and Ishiguro N (2006) Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28:33-42.
23. Van Noorden CJ (1998) Proteases and protease inhibitors in cancer. Acta Histochem 100:344-354.
24. Waxman DJ and Schwartz PS (2003) Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 63:8563-8572.
25. Wong WW, Dimitroulakos J, Minden MD, and Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519.
26. Woodhouse EC, Chuaqui RF, and Liotta LA (1997) General mechanisms of metastasis. Cancer 80:1529-1537.